TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer

TOKYO& BASKING RIDGE, N.J.--(BUSINESS WIRE) January 30, 2023 --Daiichi Sankyo (TSE: 4568) today announced that the first patient has been dosed in the global, randomized TROPION-Lung07 phase 3 trial evaluating datopotamab deruxtecan (Dato-DXd)...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials